Analyst Research Calls Impacting Biotechs (ALXN, OSCI, SGMO, VVUS, CRA)
May 29, 2008 · Filed Under daily
There were some research calls that are affecting many shares of biotech stocks this morning, as follows:
- Alexion Pharmaceuticals (NASDAQ: ALXN) started as Buy at Piper Jaffray, shares up almost 2%.
- Oscient Pharmaceuticals (NASDAQ: OSCI) started as Neutral at Piper Jaffray; shares flat as a thin volume stock.
- Sangamo Biosciences (NASDAQ: SGMO) Started as Sell at Brean Murray; shares down 11%
- Vivus (NASDAQ: VVUS) Cut to Market Perform from Outperform at Wachovia; shares down some 4%.
Elsewhere, Celera Genomics (NYSE: CRA) was started with a “Perform” rating at Oppenheimer. While Celera is a molecular diagnostic company, they are involved in the identification and validation of diagnostic markers using their own proprietary genomics and proteomics discovery platforms.
Jon Ogg
May 29, 2008